Study Group: Cardiac Surgeons who Implant HeartMate XVE Left Ventricular Assist Device
Council Members in this Study Group: 22
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
Keith AllenDirector, Cardiothoracic Vascular Surgery Research
Mid America Heart & Lung Surgeons, PC
Keith Allen, MD, is a Director of Cardiothoracic-Vascular Surgery Research at the Mid America Heart Institute in Kansas City, Missouri. He is board certified in Thoracic, Vascular, and General Surgery. Dr. Allen maintains an active clinical research department...
Jeffrey EverettDirector of Minimally Invasive and Robotic Surgery
UNIVERSITY HEALTH SYSTEM, INC.Jeffrey E. Everett, MD, is Director of Minimally Invasive and Robotic Cardiac Surgery and Associate Professor of Cardiothoracic Surgery at the University of Tennessee Medical Center. Previously, he was Director of Heart Transplantation, Minimally Invasive...
Robert GormanAssociate Professor
University of Pennsylvania - CCRobert Gorman, MD, is an Associate Professor and Director of Cardiac Surgical Research at the University of Pennsylvania. He is board certified Cardiothoracic Surgeon with clinical interests in adult cardiac surgery with a particular emphasis in valvular...
- Dale Mueller
Vice-Chairman of Cardiovascular Medicine
OSF SAINT FRANCIS MEDICAL CTRDale Mueller, MD, is a Cardiovascular and Thoracic Surgeon at Heartcare Midwest and Vice-Chairman of the Department of Cardiovascular Medicine and Surgery at OSF Saint Francis Medical Center in Illinois. He has expertise in cardiac surgery including minimally-invasive...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Drug Eluting Stents:The Next Vioxx
December 14, 2006
Trading restenosis for Thrombosis? New questions about drug-eluding stents. | content.nejm.org
1. DES whether used on or off label will likely require life long anticoagulation with Plavix like drugs.
2. The incidence of late thrombosis is significant when anticoagulation is interrupted for events such as elective surgery.
3. Unlike restenosis following insertion of a bare metal stent which rarely results in death to the patient, late thrombosis following use of a DES results in a 50% mortality.
4. Hints of this problem were present during FDA presentations prior to DES approval which may lead to significant liability as this problem becomes more apparent. -
December 4, 2006
Endarterectomy versus Stenting in Patients with Symptomatic Severe Carotid Stenosis | content.nejm.org
This study investigated carotid endarterectomy versus carotid stenting in patients with severe carotid stenosis. The study was stopped prematurely due to safety and futility. The 30-day incidence of stroke or death was 3.9% versus 9.6% for endarterectomy versus carotid stenting. This data implies that carotid stenting with cerebral protection is inferior to surgical endarterectomy, and therefore will not be as widely adopted as previous thought.
-
The forecast clears for drug eluding stents.
December 4, 2006
Trading restenosis for Thrombosis? New questions about drug-eluding stents. | content.nejm.org
This is a general commentary regarding coronary stent thrombosis and highlights the difficulties which Medtronic (Endeavor), Abbott (Xience V and Conor Medsystem (CoStar) may soon face with FDA approval of their new stents which are currently unavailable in the US. It also highlights that drug-coated stent sales have decreased while bare metal stents sales have accelerated.
-
Increased use of ventricular assist devices
December 4, 2006
Left Ventricular Assist Device and Drug Therapy for the Reversal of Heart Failure | content.nejm.org
In a series of 15 patients, the Thoratec ventricular assist device was utilized with associated medical treatment for severe non-ischemic heart failure. Eleven of the fifteen patients recovered and avoided transplantation. Key implications include increased utilization of ventricular assist devices for the indication: "bridge to recovery." This could allow patients to avoid transplantation by temporary use of a left ventricular assist device.
-
Percutaneous valves: the future is upon us!
December 4, 2006
AHA Scientific Sessions - Percutaneous Devices for Aortic Valve Disease | www.cardiosource.com
Percutaneous valves are technically feasible.
Complications are currently not comparable to the traditional open valve replacement/repair.
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Non-Academic Community Hospital or Clinic
- Office Based Private Practice or Clinic
Members in this Study Group often have these job titles:
- Physician - Director
- Physician - Attending Physician
- Physician - Department Chair
- Physician - Division Head
- Medical Director